1. Pink Sheet

Vaxneuvance, Prevnar 20 Earn CDC Cmte Nod For Age- And Risk-Based Use; Broader Shingrix Use Supported

 
• By Bridget Silverman

ACIP votes unanimously to recommend Merck and Pfizer’s pneumococcal vaccines in elderly and immunocompromised adults; GSK’s herpes zoster vaccine also gets unanimous nod for immunocompromised adults.

Lonely White Sailboat (Alamy)
VACCINES FROM PFIZER, MERCK AND GSK SAILED THROUGH THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES. • Source: Alamy

New pneumococcal conjugate vaccines from Pfizer Inc. and Merck & Co., Inc. and use of GlaxoSmithKline plc’s herpes zoster vaccine Shingrix in immunocompromised adults sailed through the Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices on 20 October, resulting in three unanimous votes to recommend use of vaccines.

ACIP has been holding to a swift pace of non-COVID-19 vaccine assessments despite the tremendously increased workload before the committee due to pandemic vaccine development. The CDC voted on the recommendations for Merck’s Vaxneuvance and Pfizer’s Prevnar 20 just three months and four and half months, respectively, following FDA approval

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.